TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38979716

Group type: COMPARATOR
Intervention: Ibandronate
Number of subjects: 35163

Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 35163

Group type: COMPARATOR
Intervention: Risedronate
Number of subjects: 35163

Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 35163

Group type: COMPARATOR
Intervention: Clodronate
Number of subjects: 35163

Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 35163

Group type: COMPARATOR
Intervention: Pamidronate
Number of subjects: 35163
Study: 38979743

Group type: COMPARATOR
Intervention: Non-oxygenated hypothermic machine perfusion (HMP)
Number of subjects: 4007

Group type: COMPARATOR
Intervention: Continuous non-oxygenated HMP
Number of subjects: 4007

Group type: COMPARATOR
Intervention: Oxygenated continuous HMP
Number of subjects: 4007

Group type: COMPARATOR
Intervention: End-ischaemic NMP (one hour)
Number of subjects: 4007
Study: 38979756

Group type: EXPERIMENTAL
Intervention: TAS-303 18 mg
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 38979812

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT)
Number of subjects: 3231

Group type: COMPARATOR
Intervention: Best medical management
Number of subjects: 3231
Study: 38979830

Group type: EXPERIMENTAL
Intervention: Intracerebral hemorrhage patients with anemia development
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Intracerebral hemorrhage patients with systemic inflammatory response syndrome (SIRS)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Intracerebral hemorrhage patients with hemoglobin changes
Number of subjects: 563
Study: 38979893

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Trastuzumab emtansine (T-DM1)
Number of subjects: 309
Study: 38980082

Group type: EXPERIMENTAL
Intervention: Stabilized hyaluronic acid (HA) spacer
Number of subjects: 136
Study: 38980207

Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 0
Study: 38980272

Group type: EXPERIMENTAL
Intervention: Empagliflozin (3-5 days)
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Empagliflozin (1-2 days)
Number of subjects: 527
Study: 38980329

Group type: EXPERIMENTAL
Intervention: QFR-guided delayed revascularization
Number of subjects: 202

Group type: COMPARATOR
Intervention: Angiography-guided delayed revascularization
Number of subjects: 202
Study: 38980511

Group type: EXPERIMENTAL
Intervention: Adipose tissue injection
Number of subjects: 9
Study: 38980664

Group type: EXPERIMENTAL
Intervention: D2+No.10 group (sLNR ≤0.4)
Number of subjects: 733

Group type: COMPARATOR
Intervention: D2 group (sLNR ≤0.4)
Number of subjects: 733
Study: 38980666

Group type: EXPERIMENTAL
Intervention: Individualized targeted heart rate aerobic exercise (n = 102)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo intervention designed to mimic relative rest (n = 96)
Number of subjects: 198
Study: 38980678

Group type: EXPERIMENTAL
Intervention: Multilevel interventions including electronic medical record changes and oral health education and skills training
Number of subjects: 1023

Group type: COMPARATOR
Intervention: AAP-based standard oral health education
Number of subjects: 1023
Study: 38980676

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) with orteronel, 300 mg orally twice daily
Number of subjects: 1279

Group type: COMPARATOR
Intervention: AD therapy with bicalutamide, 50 mg orally daily
Number of subjects: 1279
Study: 38980675

Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behavioral Therapy for Insomnia (eCBT-I) delivered over 6 weekly lesson modules with assigned homework activities.
Number of subjects: 125

Group type: COMPARATOR
Intervention: Online sleep education (control group).
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: eCBT-I group outcomes correlated with improvements in depression symptoms, PTSD symptoms, sleep quality, and fatigue impact.
Number of subjects: 125
Study: 38980710

Group type: EXPERIMENTAL
Intervention: Artificial intelligence-based self-management app (selfBACK) as an adjunct to usual care
Number of subjects: 99

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 99
Study: 38980725

Group type: EXPERIMENTAL
Intervention: Vedolizumab with ART
Number of subjects: 0
Study: 38980968

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol, 100,000 IU, five doses in 3 months)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (open-label, 100,000 IU/month for 6 months)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Whole group (both EG and CG)
Number of subjects: 88
Study: 38981063

Group type: EXPERIMENTAL
Intervention: Chronic pain survivors (N = 96; 41% of total)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Previous intravenous methotrexate treatment
Number of subjects: 233

Group type: COMPARATOR
Intervention: Respiratory chronic health conditions
Number of subjects: 233

Group type: COMPARATOR
Intervention: Gastrointestinal chronic health conditions
Number of subjects: 233

Group type: COMPARATOR
Intervention: Neurological chronic health conditions
Number of subjects: 233

Group type: COMPARATOR
Intervention: Unemployment
Number of subjects: 233

Group type: COMPARATOR
Intervention: Clinically significant depression and anxiety
Number of subjects: 233

Group type: COMPARATOR
Intervention: Diagnosis of childhood Ewing sarcoma or osteosarcoma
Number of subjects: 233

Group type: COMPARATOR
Intervention: Cardiovascular and neurological conditions, unemployment, clinical levels of depression and/or anxiety, fear of cancer recurrence
Number of subjects: 233

Group type: COMPARATOR
Intervention: Low sleep quality, elevated anxiety, and elevated depression (for male survivors)
Number of subjects: 233
Study: 38981119

Group type: EXPERIMENTAL
Intervention: Living Donor Digital Care Path
Number of subjects: 127
Study: 38981590

Group type: EXPERIMENTAL
Intervention: GWO+RuleFit
Number of subjects: 0
Study: 38981665

Group type: EXPERIMENTAL
Intervention: High-illuminance (10k lux)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Low-illuminance (4k lux)
Number of subjects: 81
Study: 38981881

Group type: EXPERIMENTAL
Intervention: Laparoscopic distal gastrectomy (LDG)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 446
Study: 38981954

Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA coadministered with FLU-QIV-HD
Number of subjects: 1029

Group type: COMPARATOR
Intervention: FLU-QIV-HD alone followed by RSVPreF3 OA at a separate visit 1 month later
Number of subjects: 1029
Study: 38981994

Group type: EXPERIMENTAL
Intervention: Pregnant women with PGP
Number of subjects: 125

Group type: COMPARATOR
Intervention: Pregnant women without PGP
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Physical activity (PA)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Kinesiophobia
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Body Image (BI)
Number of subjects: 125
Study: 38982000

Group type: EXPERIMENTAL
Intervention: Inhaled xenon combined with target temperature management (33 °C) for 24 hours
Number of subjects: 110

Group type: COMPARATOR
Intervention: Target temperature management alone
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study: 38981998

Group type: EXPERIMENTAL
Intervention: High-resolution TEMPURA
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Accelerated TEMPURA
Number of subjects: 24
Study: 38982001

Group type: EXPERIMENTAL
Intervention: Blood-based inflammatory, neuromuscular, and neurovascular biomarkers
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Blood-based biomarkers
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study: 38982051

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (PRINCE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC) chemotherapy
Number of subjects: 0
Study: 38982328

Group type: EXPERIMENTAL
Intervention: TREAT INTERACT intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mhGAP-IG training for health care personnel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (schools not receiving intervention)
Number of subjects: 0
Study: 38982339

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation (RCA) protocol for postdilution continuous veno-venous hemofiltration (CVVH)
Number of subjects: 38
Study: 38982360

Group type: EXPERIMENTAL
Intervention: Revised discharge summaries
Number of subjects: 441

Group type: COMPARATOR
Intervention: Original discharge summaries
Number of subjects: 441
Study: 38982400

Group type: EXPERIMENTAL
Intervention: BIS-guided anaesthesia
Number of subjects: 163
Study: 38982486

Group type: EXPERIMENTAL
Intervention: Serum TMAO levels
Number of subjects: 1964
Study: 38982528

Group type: EXPERIMENTAL
Intervention: Once-daily insulin glargine 300 U/mL (Gla-300)
Number of subjects: 123
Study: 38982551

Group type: EXPERIMENTAL
Intervention: High plasma calprotectin on admission and day 7
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Increasing calprotectin from admission to day 7
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Day 7 calprotectin and age
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Day 7 calprotectin alone
Number of subjects: 498
Study: 38982653

Group type: EXPERIMENTAL
Intervention: Envafolimab 2.50 mg/kg QW
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Envafolimab 150 mg QW
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Envafolimab 300 mg Q2W
Number of subjects: 182

Group type: COMPARATOR
Intervention: Weight-based dosing regimen
Number of subjects: 182

Group type: COMPARATOR
Intervention: Fixed dose regimen
Number of subjects: 182
Study: 38982903

Group type: EXPERIMENTAL
Intervention: Treatment modality A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment modality B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study: 38983151

Group type: EXPERIMENTAL
Intervention: Nintedanib 200 mg orally twice daily until disease progression or unacceptable toxicity
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 20
Study: 38983158

Group type: EXPERIMENTAL
Intervention: Nefopam 20 mg administered before surgical incision and at the end of surgery during chest tube insertion.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal saline 100 mL administered as control.
Number of subjects: 46
Study: 38983542

Group type: EXPERIMENTAL
Intervention: iOCT-guided DMEK surgery
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group without iOCT-use
Number of subjects: 65
Study: 38983653

Group type: EXPERIMENTAL
Intervention: Frailty assessment using Timed Up and Go (TUG) and Short Physical Performance Battery (SPPB) tests
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Incorporating SPPB, especially the balance test
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Effective identification and management of frailty
Number of subjects: 135
Study: 38983729

Group type: EXPERIMENTAL
Intervention: Vilaprisan (4 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Vilaprisan (2 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Vilaprisan (4 mg and 2 mg)
Number of subjects: 8
Study: 38983736

Group type: EXPERIMENTAL
Intervention: Corifollitropin α (weekly continuous dosing)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Daily follicle-stimulating hormone protocol (control)
Number of subjects: 15
Study: 38983921

Group type: EXPERIMENTAL
Intervention: Remimazolam-based total intravenous anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sevoflurane-based inhalation anesthesia
Number of subjects: 0
Study: 38984118

Group type: EXPERIMENTAL
Intervention: LCD supplement (lutein 20 mg, zeaxanthin isomers 4 mg, curcumin 200 mg, vitamin D3 600 IU)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: LCD supplement
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 38984984

Group type: EXPERIMENTAL
Intervention: Deep learning algorithm using MRI and clinical data to predict neurodevelopmental outcomes
Number of subjects: 0

Group type: COMPARATOR
Intervention: MRI data analysis
Number of subjects: 0
Study: 38985161

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 3 mg
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 7 mg
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 14 mg
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 1441
Study: 38985162

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 3 mg
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 7 mg
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 14 mg
Number of subjects: 521

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 521
Study: 38985175

Group type: EXPERIMENTAL
Intervention: Hospitalization (length of stay)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Bereavement follow-up
Number of subjects: 110
Study: 38985220

Group type: EXPERIMENTAL
Intervention: Pre-pectoral IBR
Number of subjects: 78

Group type: COMPARATOR
Intervention: Sub-pectoral IBR
Number of subjects: 78
Study: 38985232

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 56
Study: 38985247

Group type: EXPERIMENTAL
Intervention: Filgotinib (FIL) 200 mg + MTX/csDMARD
Number of subjects: 3365

Group type: COMPARATOR
Intervention: Placebo + MTX / Placebo + csDMARD
Number of subjects: 3365
Study: 38985303

Group type: EXPERIMENTAL
Intervention: CaRE-4-alloBMT rehabilitation program
Number of subjects: 80
Study: 38985408

Group type: EXPERIMENTAL
Intervention: SE travoprost intracameral implant
Number of subjects: 133

Group type: COMPARATOR
Intervention: Topical PGA monotherapy
Number of subjects: 133

Group type: COMPARATOR
Intervention: SE travoprost intracameral implant vs. Topical PGA monotherapy
Number of subjects: 133
Study: 38985436

Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg, orally, up to once daily for up to 52 weeks
Number of subjects: 1800
Study: 38985445

Group type: EXPERIMENTAL
Intervention: Cabotegravir + Rilpivirine long-acting (CAB + RPV LA) dosed every 2 months (Q2M)
Number of subjects: 430
Study: 38985461

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg once daily
Number of subjects: 2966

Group type: COMPARATOR
Intervention: Edoxaban 30 mg once daily
Number of subjects: 2966

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 2966
Study: 38985474

Group type: COMPARATOR
Intervention: Feedback
Number of subjects: 2020

Group type: COMPARATOR
Intervention: Standard incentive
Number of subjects: 2020

Group type: EXPERIMENTAL
Intervention: Standard incentive plus feedback
Number of subjects: 2020

Group type: EXPERIMENTAL
Intervention: Reframed incentive plus feedback
Number of subjects: 2020

Group type: EXPERIMENTAL
Intervention: Doubled reframed incentive plus feedback
Number of subjects: 2020
Study: 38985475

Group type: EXPERIMENTAL
Intervention: Take Good Care (TGC) intervention
Number of subjects: 451

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 451
Study: 38985480

Group type: EXPERIMENTAL
Intervention: 2-stage Turnbull-Cutait pull-through hand-sewn coloanal anastomosis
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard hand-sewn coloanal anastomosis associated with diverting ileostomy
Number of subjects: 92
Study: 38985488

Group type: EXPERIMENTAL
Intervention: 81 mg aspirin daily
Number of subjects: 15076

Group type: EXPERIMENTAL
Intervention: 325 mg aspirin daily
Number of subjects: 15076
Study: 38985492

Group type: EXPERIMENTAL
Intervention: Active aiTBS (10 sessions per day for 5 days, 90% resting motor threshold, 90,000 pulses total)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham aiTBS (10 sessions per day for 5 days, 90% resting motor threshold, 90,000 pulses total)
Number of subjects: 24
Study: 38985496

Group type: EXPERIMENTAL
Intervention: Z1 REBOA
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Z1 P-REBOA
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 16
Study: 38985561

Group type: EXPERIMENTAL
Intervention: Rezafungin (400 mg/200 mg once-weekly)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Caspofungin (70 mg/50 mg once-daily)
Number of subjects: 84
Study: 38985746

Group type: EXPERIMENTAL
Intervention: Motor training alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paper-based cognitive rehabilitation combined with motor training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digital-based cognitive rehabilitation coupled with motor training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38985785

Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin for 1-5 month-olds during trachoma MDA
Number of subjects: 1735

Group type: EXPERIMENTAL
Intervention: Post-MDA coverage survey
Number of subjects: 1735

Group type: EXPERIMENTAL
Intervention: Qualitative data from parents, CDDs, and supervisors
Number of subjects: 1735
Study: 38985796

Group type: EXPERIMENTAL
Intervention: Ciprofol
Number of subjects: 136

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 136
Study: 38985817

Group type: EXPERIMENTAL
Intervention: CO2 gas-based cryotherapy
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Non-gas cryotherapy
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Thermal ablation (TA)
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Adherence to post-treatment recommendations
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Overall incidence of gynecologic infection
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Non-gas cryotherapy and TA
Number of subjects: 864
Study: 38985849

Group type: EXPERIMENTAL
Intervention: TARE/Chemo
Number of subjects: 303

Group type: COMPARATOR
Intervention: Chemo
Number of subjects: 303
Study: 38985979

Group type: EXPERIMENTAL
Intervention: LIS1 (0.6, 1, 3, 6, 8, or 10 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: LIS1 (8 mg/kg and 10 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: LIS1
Number of subjects: 10
Study: 38985986

Group type: EXPERIMENTAL
Intervention: RSV-LRTI<2Y
Number of subjects: 1395
Study: 38986058

Group type: EXPERIMENTAL
Intervention: Nirsevimab therapy
Number of subjects: 1035

Group type: COMPARATOR
Intervention: Control group (no nirsevimab)
Number of subjects: 1035
Study: 38986134

Group type: EXPERIMENTAL
Intervention: PatientCareAnywhere intervention
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 36
Study: 38986210

Group type: EXPERIMENTAL
Intervention: pemi/gem/cis
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: pemi/doc
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: pemi/tras
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: pemi/pembro
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: pemi/reti
Number of subjects: 65
Study: 38986212

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily
Number of subjects: 15
Study: 38986421

Group type: EXPERIMENTAL
Intervention: Capmatinib 400 mg bid plus nazartinib 100 mg qd (RP2D)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Capmatinib 400 mg bid plus nazartinib 100 mg qd (RP2D) in group 1 + phase 1b RP2D
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Capmatinib plus nazartinib
Number of subjects: 144
Study: 38986541

Group type: EXPERIMENTAL
Intervention: 0.1 mL of 24% sucrose administered 2 min prior to painful procedures
Number of subjects: 172
Study: 38986553

Group type: EXPERIMENTAL
Intervention: EuroQol five-dimension five-level (EQ5D-5L)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Gastrointestinal Quality Life Index-36
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire-9
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Generalised Anxiety Disorder 7
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: International Trauma Questionnaire
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Caregiver Interaction Scale
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Fatigue Severity Scale
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with patient participants
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with family caregivers
Number of subjects: 160
Study: 38986555

Group type: EXPERIMENTAL
Intervention: Pathway Navigation (PN) intervention, which includes a postal appointment notification and a prearranged telephone appointment with a pathway navigator.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pathway Navigation (PN) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (a further postal invitation to contact the screening service for a lung health check)
Number of subjects: 0
Study: 38986575

Group type: EXPERIMENTAL
Intervention: Tailored treatment plans
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Clinician-led decisions
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Communication adjuncts
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Clinical decision aids
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Repetition of information
Number of subjects: 25
Study: 38986608

Group type: EXPERIMENTAL
Intervention: 25 mg/kg HLX22 + HLX02 + XELOX (group A)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 15 mg/kg HLX22 + HLX02 + XELOX (group B)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo + HLX02 + XELOX (group C)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 53
Study: 38986627

Group type: EXPERIMENTAL
Intervention: 240mL of coffee with 6mg/caffeine/kg of weight
Number of subjects: 0

Group type: COMPARATOR
Intervention: 240mL of water
Number of subjects: 0
Study: 38986667

Group type: EXPERIMENTAL
Intervention: Aldose reductase inhibitor
Number of subjects: 691
Study: 38986791

Group type: EXPERIMENTAL
Intervention: Oral treprostinil
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Common side effect treatments (acetaminophen, loperamide, ondansetron)
Number of subjects: 139
Study: 38986891

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo control, mock laser (ML) acupuncture
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups (EA and ML)
Number of subjects: 76
Study: 38987020

Group type: EXPERIMENTAL
Intervention: Laparoscopic robotic abdominal surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparoscopic non-robotic abdominal surgery
Number of subjects: 0